UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO.

5,089,509

ISSUED

February 18, 1992

INVENTOR

Roshantha A. S. Chandraratna

PATENT OWNER

Allergan, Inc.

PRODUCT

TAZORAC® (tazarotene)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the U.S. Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 5,089,509 based upon the regulatory review of the product TAZORAC® (tazarotene) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

845 days

from February 18, 2009, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).

I have caused the seal of the U.S. Patent and Trademark Office to be affixed this 12th day of September 2000.

Q. Todd Dickinson

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and

Trademark Office